← AI Health Hub

Genetics 4 min read

Precision oncology through next generation sequencing in hepatocellular carcinoma.

Next-Generation Sequencing enhances precision medicine in hepatocellular carcinoma, addressing drug resistance and improving treatment outcomes. ๐Ÿงฌ๐Ÿ”ฌ

Yusuf Yesil, MD, MIS

โšก Quick Summary

This article discusses the role of Next-Generation Sequencing (NGS) in enhancing precision oncology for hepatocellular carcinoma (HCC), a primary liver cancer often linked to viral infections. By identifying mutations and genetic heterogeneity, NGS paves the way for personalized treatment strategies, potentially reducing tumor relapse rates.

๐Ÿ” Key Details

  • ๐Ÿ“Š Focus: Hepatocellular carcinoma (HCC)
  • ๐Ÿงฌ Technology: Next-Generation Sequencing (NGS)
  • ๐Ÿฆ  Associated Infections: Hepatitis B virus (HBV) and Hepatitis C virus (HCV)
  • โš™๏ธ Objective: To develop personalized treatment strategies through genetic insights

๐Ÿ”‘ Key Takeaways

  • ๐Ÿ”ฌ NGS is crucial for identifying mutations in both viral and host genomes.
  • ๐Ÿ’ก Personalized medicine is becoming a reality in HCC treatment.
  • โš ๏ธ Drug resistance remains a significant challenge in HCC management.
  • ๐Ÿค– AI integration could further enhance the capabilities of NGS in oncology.
  • ๐Ÿ“ˆ Advances in NGS have led to higher accuracy and throughput in sequencing.
  • ๐Ÿงฉ Combination therapies are being developed to counteract drug-resistant mutations.
  • ๐ŸŒ Study published in Heliyon, highlighting the importance of ongoing research.

๐Ÿ“š Background

Hepatocellular carcinoma (HCC) is a major health concern, often arising from chronic liver inflammation due to viral infections such as HBV and HCV. Despite existing treatment options, the high rates of tumor relapse and the emergence of drug resistance complicate patient outcomes. The integration of advanced technologies like NGS offers a promising avenue for improving treatment efficacy and personalizing patient care.

๐Ÿ—’๏ธ Study

The study emphasizes the transformative potential of Next-Generation Sequencing (NGS) in the realm of precision oncology for HCC. By sequencing both the viral and host genomes, researchers can uncover critical mutations and genetic variations that contribute to the disease’s progression and treatment resistance. This knowledge is essential for developing targeted therapies that can effectively address these challenges.

๐Ÿ“ˆ Results

The advancements in NGS technology have resulted in higher accuracy and throughput, enabling researchers to gather comprehensive genetic data. This data is instrumental in identifying specific mutations that may lead to drug resistance, thereby informing the development of combination therapies tailored to individual patient profiles.

๐ŸŒ Impact and Implications

The implications of this research are profound. By leveraging NGS, healthcare providers can move towards a more personalized approach in treating HCC, potentially improving patient outcomes and reducing the likelihood of tumor relapse. Furthermore, the integration of artificial intelligence (AI) could enhance the analysis of genetic data, leading to even more refined treatment strategies.

๐Ÿ”ฎ Conclusion

This article highlights the significant role of Next-Generation Sequencing in advancing precision oncology for hepatocellular carcinoma. As we continue to explore the genetic underpinnings of this disease, the potential for personalized treatment strategies becomes increasingly tangible. The future of HCC management looks promising, with ongoing research and technological advancements paving the way for better patient care.

๐Ÿ’ฌ Your comments

What are your thoughts on the integration of NGS in treating hepatocellular carcinoma? We would love to hear your insights! ๐Ÿ’ฌ Join the conversation in the comments below or connect with us on social media:

Precision oncology through next generation sequencing in hepatocellular carcinoma.

Abstract

Hepatocellular carcinoma (HCC) is a primary liver cancer that originates from underlying inflammation, often associated with Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infections. Despite the availability of treatments, there are high rates of tumour relapse due to the development of drug resistance in infected cells. Next-Generation Sequencing (NGS) plays a crucial role in overcoming this issue by sequencing both viral and host genomes to identify mutations and genetic heterogeneity. The knowledge gained from sequencing is then utilised to develop countermeasures against these mutants through different combination therapies. Advances in NGS have led to sequencing with higher accuracy and throughput, thereby enabling personalized and effective treatments. The purpose of this article is to highlight how NGS has contributed to precision medicine in HCC and the possible integration of artificial intelligence (AI) to bolster the advancement.

Author: [‘Shinde S’, ‘Bigogno CM’, ‘Simmons A’, ‘Kathuria N’, ‘Ghose A’, ‘Apte V’, ‘Lapitan P’, ‘Makker S’, ‘Caglayan A’, ‘Boussios S’]

Journal: Heliyon

Citation: Shinde S, et al. Precision oncology through next generation sequencing in hepatocellular carcinoma. Precision oncology through next generation sequencing in hepatocellular carcinoma. 2025; 11:e42054. doi: 10.1016/j.heliyon.2025.e42054

This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment.

Yusuf Yesil, MD, MIS
Yusuf Yesil, MD, MIS

Founder & Medical Doctor at Yesil Science. Clinical Biochemistry Specialist and Health AI researcher focused on clinical decision support, diagnostic AI, and biomedical machine learning.

Follow AI Health Hub